EASL2019 THU-237 选择骨/肾脏的适应症的患病率增加 抗病毒药物

StephenW

THU-237
Increasing prevalence of indications to choose bone/renalfriendly
antiviral drug: A territory-wide study of 135, 414 patients
from 2000 to 2017
Grace Lai-Hung Wong1, Becky Wing-Yan Yuen1, Yee-Kit Tse2,
Hester Wing-Sum Luk1, Terry CF Yip1, Henry Chan1,
VincentWai-SunWong1. 1The Chinese University of Hong Kong, Shatin,
Hong Kong; 2The Chinese University of Hong Kong, Shatin, Hong Kong
Email: [email protected]
Background and aims: The latest clinical practice guideline from
European Association for the Study of the Liver (EASL) published in
2017 advocate the use of entecavir or tenofovir alafenamide (TAF)
over tenofovir disoproxil fumarate (TDF) according to age, bone
disease and renal alteration. As patients with chronic hepatitis B
(CHB) are ageing with improved survival under better healthcare,
more patients may fulfil these criteria. We aimed to determine the
prevalence of these criteria in the territory-wide CHB cohort in Hong
Kong over 18 years from year 2000 to 2017.
Method: CHB patients who have been under the care at primary,
secondary and tertiary medical centers in the public sector in Hong
Kong were identified through the Clinical Data Analysis and
Reporting System of the Hospital Authority. The demographics and
prevalence of relevant bone and renal co-morbidities, and relevant
laboratory parameters were determined according to patients’ first
appearance in four time periods: 2000-2004, 2005-2009, 2010-2013
and 2014-2017.
Results: 136, 414 CHB patients were included. The prevalence of the
above criteria increased over the four periods: age >60 years 11.6%,
20.4%, 27.6% and 35.4%; Steroid/medications that worsen bone
density 57.2%, 50.5%, 56.0% and 61.8% respectively; albuminuria
0.2% 0.4% 0.7% and 1.1% respectively, and low phosphate (<2.5 mg/dl)
3.9%, 4.0%, 5.1% and 7.0% respectively (all P < 0.001; Figure).
Conclusion: CHB patients are getting older with increasing prevalence
of indications to choose entecavir or TAF over TDF according to
the latest EASL guidelines.
Funding: This work was supported by the Investigator Sponsored
Research of Gilead Sciences (Reference: IN-US-988-5290).

StephenW

THU-237
选择骨/肾脏的适应症的患病率增加
抗病毒药物：一项针对135,414名患者的全港性研究
从2000年到2017年
Grace Lai-Hung Wong1，Becky Wing-Yan Yuen1，Yee-Kit Tse2，
Hester Wing-Sum Luk1，Terry CF Yip1，Henry Chan1，
VincentWai-SunWong1。 1沙田香港中文大学
香港; 2香港中文大学，香港沙田
电邮：[email protected]
背景和目的：最新的临床实践指南
欧洲肝脏研究协会（EASL）发表于
2017年主张使用恩替卡韦或替诺福韦艾拉酚胺（TAF）
超过替诺福韦地索普西富马酸盐（TDF）根据年龄，骨骼
疾病和肾脏改变。作为慢性乙型肝炎患者
（CHB）老化，在更好的医疗保健下提高生存率，
更多患者可以满足这些标准。我们的目的是确定
这些标准在香港的全港CHB队列中普遍存在
从2000年到2017年，香港超过18年。
方法：接受过初级保健的CHB患者，
香港公共部门的二级和三级医疗中心
通过临床数据分析确定了香港
医院管理局的报告制度。人口统计学和
相关的骨和肾共病的患病率和相关性
实验室参数根据患者首先确定
出现在四个时期：2000-2004,2005-2009,2010-2013
和2014  -  2017年。
结果：包括136,414名CHB患者。流行的
以上标准在四个时期内增加：年龄> 60岁11.6％，
20.4％，27.6％和35.4％;类固醇/药物会使骨骼恶化
密度分别为57.2％，50.5％，56.0％和61.8％;蛋白尿
0.2％0.4％0.7％和1.1％，低磷酸盐（<2.5 mg / dl）
分别为3.9％，4.0％，5.1％和7.0％（均P <0.001;图）。
结论：CHB患者随着患病率的增加而逐渐变老
有关根据TDF选择恩替卡韦或TAF超过TDF的适应症
最新的EASL指南。
资助：这项工作得到了研究者赞助的支持
吉利德科学研究（参考文献：IN-US-988-5290）。